Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
€ 0.02
Key Takeaways
Risk factor
Considerable default risk
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME);...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, of fair value on EV/EBITD.
Data is available to registered users only
